Education
About Us
Working with TipRanks
Follow Us
Ventyx Biosciences (VTYX)
NASDAQ:VTYX
VTYX Stock Chart & Stats
$3.92
-$0.21(-8.13%)
At close: 4:00 PM EST
$3.92
-$0.21(-8.13%)
Day’s Range― - ―
52-Week Range$0.78 - $4.12
Previous CloseN/A
Volume4.54M
Average Volume (3M)1.30M
Market Cap
$279.53M
Enterprise Value-$46.30M
Total Cash (Recent Filing)$208.96M
Total Debt (Recent Filing)$10.29M
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Nov 12, 2025EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding71,308,520
10 Day Avg. Volume1,359,554
30 Day Avg. Volume1,304,464
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.17
Enterprise Value/Revenue-31.97
Enterprise Value/Gross Profit-503.25
Enterprise Value/Ebitda0.40
Forecast
1Y Price Target
$13.75Price Target Upside250.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical TrialsVentyx is conducting an open-label Phase 2 study with an orally administered, peripherally restricted NLRP3 inhibitor, VTX2735, in patients with recurrent pericarditis.
Product DevelopmentVTX2735 as an oral option could potentially be more convenient for patients as rilonacept requires injection.
Research & InnovationVTX3232 combined with semaglutide led to additive reductions in body weight and food intake, showing potential for improved treatment outcomes.
Bears Say
Market CompetitionThe company is not focusing on monotherapy for obesity as the market is highly competitive, indicating challenges in this strategy.
Strategic ChallengesA significant increase over semaglutide alone is needed to justify the combination approach, presenting a challenge for the company's strategy.
Ventyx Biosciences News
VTYX FAQ
What was Ventyx Biosciences’s price range in the past 12 months?
Ventyx Biosciences lowest stock price was $0.78 and its highest was $4.12 in the past 12 months.
What is Ventyx Biosciences’s market cap?
Ventyx Biosciences’s market cap is $279.53M.
When is Ventyx Biosciences’s upcoming earnings report date?
Ventyx Biosciences’s upcoming earnings report date is Nov 12, 2025 which is in 22 days.
How were Ventyx Biosciences’s earnings last quarter?
Ventyx Biosciences released its earnings results on Aug 07, 2025. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.47 by $0.09.
Is Ventyx Biosciences overvalued?
According to Wall Street analysts Ventyx Biosciences’s price is currently Undervalued.
Does Ventyx Biosciences pay dividends?
Ventyx Biosciences does not currently pay dividends.
What is Ventyx Biosciences’s EPS estimate?
Ventyx Biosciences’s EPS estimate is -0.45.
How many shares outstanding does Ventyx Biosciences have?
Ventyx Biosciences has 71,308,520 shares outstanding.
What happened to Ventyx Biosciences’s price movement after its last earnings report?
Ventyx Biosciences reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.47. Following the earnings report the stock price went up 19.068%.
Which hedge fund is a major shareholder of Ventyx Biosciences?
Currently, no hedge funds are holding shares in VTYX
Ventyx Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.75 (250.77% Upside)
$13.75 (250.77% Upside)
Blogger Sentiment
Bearish
VTYX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 661.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.00%
12-Months-Change
Fundamentals
Return on Equity
-48.56%
Trailing 12-Months
Asset Growth
-25.61%
Trailing 12-Months
Company Description
Ventyx Biosciences
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
VTYX Stock 12 Month Forecast
Average Price Target
$13.75
▲(250.77% Upside)
Technical Analysis
Immutep
―
Voyager Therapeutics
―
Silence Therapeutics
―
Foghorn Therapeutics
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
9.73% Insiders
7.68% Mutual Funds
26.36% Other Institutional Investors
51.34% Public Companies and
Individual Investors